Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

30.19 -1.05 (-3.36%)
Streaming Delayed Price Updated: 10:01 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish
Tempest Therapeutics Inc (NASDAQ: TPST) announced  
Via Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
The company reported lighter-than-expected declines due to Keytruda and Gardasil. 
Via Investor's Business Daily
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)  
Via Benzinga
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
Both GSK and Roche experienced declining Covid-related sales in the first quarter. 
Via Investor's Business Daily
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at... 
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Is Roche a Buy Now?
Roche focuses on the long-term. 
Via The Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.  
Via Benzinga
Biogen To Report Q1 Earnings: Here's What To Expect
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%. 
Via Talk Markets
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma
Via Benzinga
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
The company bulks up its pipeline by regaining the rights to two of its clinical programs. 
Via The Motley Fool
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
Shares are closing in on a buy point out of a consolidation. 
Via Investor's Business Daily
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
Via Benzinga
Roche's Slow Growth Shouldn't Drive Investors Away
New treatments for various cancers, eye diseases, and more may bring in future revenues. 
Via The Motley Fool
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
Via Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
Via Benzinga
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
Via Benzinga
Daily Stock Analysis: Roche Holding AG
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was... 
Via Talk Markets
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
Via Benzinga
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Via Benzinga
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval. 
Via The Motley Fool
3 Best Growth Stocks to Buy In March
These three red-hot growth stocks have more room to run. 
Via The Motley Fool
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
Via Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients. 
Via Investor's Business Daily
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.